Was ist gesichert in der Therapie chronisch-entzündlicher Darmerkrankungen
Author:
Publisher
Springer Science and Business Media LLC
Subject
Internal Medicine
Link
https://link.springer.com/content/pdf/10.1007/s00108-021-01207-6.pdf
Reference56 articles.
1. Burisch J, Jess T, Martinato M, Lakatos PL (2013) ECCO-EpiCom: The burden of inflammatory bowel disease in Europe. J Crohn’s Colitis 7(4):322–337
2. Molodecky NA, Soon S, Rabi DM, Ghali WA, Ferris M, Chernoff G, Benchimol EI, Panaccione R, Ghosh S, Barkema HW (2012) Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 142(1):46–54.e42
3. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JC, Chan FK (2017) Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 390(10114):2769–2778
4. Schnorbach M‑T, Kruis W (2020) Krankheitskosten chronisch entzündlicher Darmerkrankungen in Deutschland. Z Gastroenterol. https://doi.org/10.1055/a-1174-0670
5. Abraham BP, Mehta S, El-Serag HB (2012) Natural history of pediatric-onset inflammatory bowel disease: a systematic review. J Clin Gastroenterol 46(7):581
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Switching within versus out of class following first-line TNFi failure in ulcerative colitis: real-world outcomes from a German claims data analysis;Therapeutic Advances in Gastroenterology;2024-01
2. Treatment strategies in inflammatory bowel diseases;Deutsches Ärzteblatt international;2023-11-10
3. Themen – Stellungnahme zur Nutzenbewertung von Risankizumab (Morbus Crohn, vorbehandelte Patient*innen) vom 24. April 2023;Zeitschrift für Gastroenterologie;2023-06
4. Bioactive Components and Potential Mechanism Prediction of Kui Jie Kang against Ulcerative Colitis via Systematic Pharmacology and UPLC-QE-MS Analysis;Evidence-Based Complementary and Alternative Medicine;2022-06-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3